In Vivo CAR Target opportunities in vivo CAR therapies for cancer, autoimmunity, and fibrosis leveraging CREATE Medicines' proprietary mRNA-LNP platform for direct immune cell programming and off-the-shelf immunotherapies.

Clinical Pipeline Focus on advancing MT-302 in TROP2 cancers as a first-line option, presenting a path for strategic partnerships or collaborations with larger oncology players seeking novel first-line therapies.

Funding Momentum Capital infusion from a $122M Series B signals strong investor confidence and should be leveraged to accelerate clinical milestones, pursue co-development deals, and expand manufacturing or regulatory capabilities.

Strategic Expansion Recent executive and scientific advisory hires strengthen governance and scientific credibility, offering opportunities to co-develop programs, access expert networks, and enhance partnering conversations with potential collaborators.

Clinical-Stage Position As a clinical-stage biotech with a growing cancer-focused pipeline and autoimmune preclinical programs, identify alliance opportunities with CROs, biopharma partners, and venture groups active in immuno-oncology and RNA-based therapeutics.